Athersys maintains a broad intellectual intellectual property estate related to its core technologies and product development programs. Intellectual property may include including composition of matter, methods of manufacturing,and/or method of usage, as appropriate, and may be related to specific proprietary product candidates as well as technology platforms.
Athersys' maintains a broad portfolio of intellectual property related to MultiStem. Currently the company has a range of issued and pending patents that includes composition of matter, methods of manufacturing, methods of use in broadly defined or specific therapeutic indications, and other areas. Currently the company has more than 50 issued patents internationally related to MultStem, with over 40 patent families and over 160 distinct applications.
The company also has multiple issued patents on other product development candidates and related areas.
In addition to intellecutaual property related to specific therapeutic products and programs, Athersys has extensive intellectual property related to its proprietary technologies. The RAGE technology portfolio includes 11 issued U.S. patents, and multiple pending U.S. patent applications, and various corresponding international patents and patent applications. Further, Athersys has also filed patent applications covering novel human gene sequences and new drug targets discovered using RAGE, and multiple applications directed to novel mutation methods (GECKO technology).